 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...1415161718192021222324...143144» |
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - May 8, 2023
P2, N=36, Active, not recruiting, Sponsor: Trisha Wise-Draper
Trial primary completion date: Mar 2023 --> Dec 2023
- || Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment closed, Metastases: NAUTICALCRC: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. (clinicaltrials.gov) - May 8, 2023
P2, N=103, Active, not recruiting, Sponsor: Pierre Fabre Medicament
Trial primary completion date: Mar 2023 --> Dec 2023 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report. (Pubmed Central) - May 6, 2023
The combination of cetuximab with oxaliplatin-based chemotherapy is commonly utilized as a systemic treatment for metastatic CRC. Hereby, we report a case of BM from CRC with significant response after capecitabine and oxaliplatin (XELOX) combined with cetuximab.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: Molecular prognostic factors in colorectal cancer: 5-year follow-up. (Pubmed Central) - May 6, 2023
Using the Kaplan-Meier test, we calculated the correlation coefficient between survival time and immunohistochemical prognostic factors. The patients were followed for 60 months postoperatively.
- | PF-07284892 / Pfizer
Trial completion date, Combination therapy, Metastases: PF-07284892 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2023
P1, N=196, Recruiting, Sponsor: Pfizer
The patients were followed for 60 months postoperatively. Trial completion date: Apr 2026 --> Sep 2026
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
The promising role of TGF-?RII mutations and EGFR immunostaining in response to anti-EGFR therapies (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_646;
The approach we propose through these research results has the potential to adapt current targeted therapies (anti-EGFR) to the biological characteristics of sporadic CRC through TGF? pathway and could thus decrease the risk of administering expensive and potentially toxic treatments to patients unnecessarily.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_631;
P3
This type of visualization can help heath care givers to better predict EC side effects which is generally well tolerated in most patients, with most AEIs being mild to moderate in severity. Analyses providing novel visual aids to support the interpretation of safety profiles of EC should help oncologists and heath care givers in daily clinical practice to improve overall outcomes for patients.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Skin rash as a predictor of tumor response to EGFR inhibitors in advanced colorectal cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_608;
Skin toxicities are the most common adverse events with EGFR inhibitors. The acneiform rash is a good predictor of tumor response in EGFR inhibitors therapy.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Safety and efficacy of short cetuximab infusion for patients with metastatic colorectal cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_606;
This led to shorter visit and chair time during the covid19 pandemic. This has the potential of saving time on chemotherapy chair, and associated healthcare costs.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
The contribution of circulating tumor cells' gene expression in treatment response (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_593;
These preliminary data indicate that not all cases exhibit the same behavior, as it was expected. There are overexpressed genes, whose expression associated with response to chemotherapeutic drugs, like fluorouracil, oxaliplatin, irinotecan, monoclonal antibodies, such as nivolumab, cetuximab etc. However, these genes are not upregulated in all cases, since there is a percentage of approximately 30% with different expression profile.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
ERBB2 mutations in metastatic colorectal cancer: From clinicopatholgical features to potential treatment implications in a real-world cohort (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_575;
We found an addition 4.4% ERBB2 VUS prevalence, with a ERBB2 mutation prevalence of 7.5% as a whole. Pathogenetic mutations can co-occur with other driver molecular alterations.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Epidemiology and management of locally advanced and metastatic colorectal cancer RAS wild type: A retrospective study of 70 patients (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_489;
The mean age: 50,14 years ( 24 -76 ), Sex: 45 men, 25 female, sex ratio : 1,8, Who 0: 3pts, Who 1: 64pts, Who 2: 3pts. The combination chemotherapy with monoclonal antibodies to the EGFR, and the strategy in the multidisciplinary management can extend median survival and improve the prognosis.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107 (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_473;
P2
Evaluation of serial RNA profiles collected from patient samples on this study demonstrated that a decreased MAPK signature and increased interferon gamma signature following treatment with E + C + N were associated with sustained treatment benefit. We hypothesize that PFS will be improved by the addition of N to E + C for patients with MSS, BRAFV600E mCRC.Clinical trial identification: NCT05308446.Legal entity responsible for the study: The authors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Efficacy and tolerability of cetuximab 750 mg/m2 every three weeks in metastatic colorectal cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_455;
The small sample size is a limitation of the above conclusion. A prospective evaluation of the above regimen is warranted.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Tumor response as a predictor of survival for RAS-WT left-sided mCRC administered first-line molecularly targeted drugs: An observational study by the Japanese Society for Cancer of the Colon and Rectum (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_441;
In the RES group, PFS and OS were similar between BEV and CET/PAN, but in the nRES group, BEV showed better survival compared with CET/PAN. These results indicate that the survival benefit of CET/PAN is less than that of BEV in the non-response group.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
BRAF mutant metastatic colon cancer expect the unexpected: A single centre study (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_428;
Despite the availability of cetuximab/ encorafinib from early 2020 in second line indication only 9 patients (19%) received second-line BRAF inhibitor therapy. In conclusion there should be a low threshold to investigate any reported symptoms with possibility of metastases in mind in patients with BRAF mutated colon cancer as they can exhibit an atypical pattern of metastatic spread.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_410;
CET/PAN may have limited efficacy and may be more toxic in elderly patients with RAS WT colorectal cancer. These findings should be considered when treating elderly patients with RAS WT colorectal cancer, and appropriate management of side effects is needed for elderly patients receiving CET/PAN.
- Elunate (fruquintinib) / Takeda
Efficacy, safety, and predictors of fruquintinib plus PD-1 in refractory MSS metastatic colorectal cancer in a real-world setting (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_390;
The combination of fruquintinib and PD-1 is a promising treatment option with a tolerable toxicity profile for refractory microsatellite-stable metastatic CRC patients. In particular, for those with liver metastases, the addition of local treatment can significantly prolong patient survival and warrants further investigation to confirm its efficacy.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Retrospective analysis of management of BRAF V600E mutated colorectal cancer in a single institution (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_383;
Our study emphasizes the poor prognosis of BRAF V600E-mutated metastasic colorrectal cancer, In our population, similar as the one in the BEACON study, the combination of encorafenib-cetuximab stands out as a well-tolerated option in second line, with a PFS of 9,9 months. Of note, in our experience encorafenib-cetuximab could also be a remarkable option in third-line setting, with a PFS of 10,4 months.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Detection of RAS gene mutations in patients with metastatic colorectal cancer during cetuximab-based first-line treatment and survival of the patients in relation to changes in RAS gene status (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_380;
Our findings indicate that a change in RAS status is a negative prognostic factor for the second-line treatment, but this needs to be confirmed in large-scale studies. Testing RAS status analysing ctDNA might help to stratify patients during the metastatic treatment and to personalize the ongoing therapy.
- PD1 and LAG3 inhibition as second+ line treatment after EGFR antibody-containing therapy in RAS/BRAF wildtype, MMRp metastatic colorectal cancer (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_356;
P2
However, the clinical benefit rate in pts without liver metastases and prolonged disease control in two pts with liver metastases are encouraging. Nivolumab/relatlimab was well tolerated.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_335;
Having a DpR of at least 15% predicts longer PFS and OS in patients with BRAFV600E mut mCRC receiving TT as second-line treatment. An independent cohort of pts treated with second-line chemotherapy +/- antiangiogenic is under investigation as control group.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study (Poster HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_268;
The clinical outcomes of the BEACON triplet regimen in the Japanese patients with BRAF V600E-mutant mCRC were consistent with those in the BEACON CRC study. These results support that the BEACON triplet regimen is one of the standard treatment for pretreated Japanese patients with BRAF V600E-mutant mCRC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Disease characteristics and real-world treatment pathways of BRAF V600E-mutant metastatic colorectal cancer patients: Analysis of 120 patients enrolled in the BERING CRC study (POSTER HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_241;
P=N/A
However, compared to literature, synchronous metastases were reported considerably more often in this NIS. Compared to the pivotal study BEACON CRC, BERINGCRC patients were notably older and less patients were documented with ECOG PS 0.
- Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in metastatic colorectal cancer (mCRC) patients (POSTER HALL LEVEL 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_237;
P2
In MSS mCRC, LOH-high was associated with biallelic alterations in the HRR system, worse prognosis and higher benefit from the addition of anti-PDL1 agents to chemotherapy. Considering the low number of LOH-high tumors in our study, these results deserve confirmation in larger cohorts.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis (Auditorium B, Level 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_215;
P3
In the BEACON CRC study, patient characteristics and outcomes were generally similar between those who received E+C in 2L and those who received it in 3L. First-line E+C with or without chemotherapy is currently under investigation in the BREAKWATER study (NCT04607421).
- Bavencio (avelumab) / EMD Serono, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO (Auditorium B, Level 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_213;
P2
AVETRIC study met its primary endpoint, showing that combining mFOLFOXIRI plus cet and ave achieves promising results in terms of PFS as well as response rate, in pts with pMMR RAS and BRAF wt mCRC. Translational analyses to evaluate the impact of immune-related biomarkers are ongoing.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCRO (Auditorium B, Level 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_211;
P2
m-FOLFOXIRI plus cet regimen could be a good option for upfront chemotherapy in mCRC pts with RAS/BRAF wild-type and left-sided primary tumor. Further survival analysis will be performed by updated BRAF information from a biomarker study using tissue samples.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT) (Auditorium A, Level 0) - May 6, 2023 - Abstract #ESMOGI2023ESMO_GI_206;
pMMR/MSS BRAF V600E mut mCRC patients achieve benefit from TT vs CT independently of RNF43 mutational status, but a higher magnitude of benefit from TT is observed among those with RNF43 mut tumors. These findings deserve confirmation in past and current randomized trials (i.e. BEACON and BREAKWATER).
- || Cablivi (caplacizumab) / Sanofi, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
I think you have to draw the line somewhere. Otherwise we’ll go crazy with including cetuximab and trastuzumab or (god forbid) caplacizumab. (Twitter) - May 3, 2023
- || TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Review, Journal, Combination therapy, Metastases: Cetuximab or nimotuzumab in combination with chemotherapy for treating recurrent/metastatic nasopharyngeal carcinoma: A meta?analysis and systemic review. (Pubmed Central) - May 1, 2023
In addition, all grade 3-4 adverse events from the included studies were gathered. In conclusion, the use of CTX or NTZ in combination with chemotherapy may be a feasible and safe option for treating RM-NPC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal, Metastases: Induction Chemotherapy With 5-Fluorouracil, Cisplatin, and Cetuximab in Advanced Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - May 1, 2023
The efficacy of ICT was comparable between the FPE and TPF groups, whereas FPE was associated with less toxicity. It is suggested that FPE therapy is an alternative ICT regimen to TPF therapy, but further long-term follow-up is needed.
- || FT536 / Fate Therap
Enrollment closed, Enrollment change, Combination therapy, Monotherapy, Metastases: FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (clinicaltrials.gov) - May 1, 2023
P1, N=5, Active, not recruiting, Sponsor: Fate Therapeutics
It is suggested that FPE therapy is an alternative ICT regimen to TPF therapy, but further long-term follow-up is needed. Recruiting --> Active, not recruiting | N=322 --> 5
- || FT538 / Fate Therap
Enrollment closed, Enrollment change, Combination therapy, Metastases: FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors (clinicaltrials.gov) - May 1, 2023
P1, N=16, Active, not recruiting, Sponsor: Fate Therapeutics
Recruiting --> Active, not recruiting | N=322 --> 5 Recruiting --> Active, not recruiting | N=189 --> 16
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal, Circulating tumor cells, Tumor cell: Circulating tumor cell abundance in head and neck squamous cell carcinoma decreases with successful chemoradiation and cetuximab treatment. (Pubmed Central) - Apr 28, 2023
Interestingly, two patients with recurrent disease had elevated CTC counts during and following treatment, which also correlated with growth of size and ki67 expression in the primary tumor. The results suggest that our device may be a valuable tool for evaluating the success of less intensive treatment regimens.
- | MEN1611 / Menarini
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) (clinicaltrials.gov) - Apr 28, 2023
P1/2, N=42, Active, not recruiting, Sponsor: Menarini Group
The results suggest that our device may be a valuable tool for evaluating the success of less intensive treatment regimens. Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023
- || anzurstobart (BMS-986351) / BMS, Erbitux (cetuximab) / Eli Lilly
Enrollment closed, Combination therapy, Metastases: CC-95251-ST-001: A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers (clinicaltrials.gov) - Apr 28, 2023
P1, N=230, Active, not recruiting, Sponsor: Celgene
Recruiting --> Active, not recruiting | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2023 --> Oct 2023 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 27, 2023
P2, N=24, Active, not recruiting, Sponsor: University of Cincinnati
Recruiting --> Active, not recruiting Trial completion date: Oct 2022 --> Oct 2023
- || MK-1084 / Merck (MSD), Otsuka
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) - Apr 27, 2023
P1, N=450, Recruiting, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Oct 2022 --> Oct 2023 N=264 --> 450 | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5705;
Flexible chemotherapy backbones, such as TP/DP-HDFL(weekly docetaxel or paclitaxel with cisplatin and 24-hr high dose 5-fluorouracil/leucovorin infusion), might produce acceptable response rates with less toxicity. Bio(EGFR or VEGFR-targeting)-chemotherapy or Bio-chemoimmunotherapy has brought encouraging induction response with favorable toxicity profiles to conversion surgery or definite CCRT.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Real-world survival of older adults with LA SCCHN using SEER-Medicare. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5696;
mOS was lower in patients who received non-DT vs DT. Despite available treatment options, there remains a need for novel therapies that can improve outcomes in LA SCCHN.
- TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Nimotuzumab in combination with intensity modulated radiotherapy improve survival in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A multicenter-based real-world study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5644;
P=N/A
6 weeks and CCRT. Clinical trial information: NCT04949503.
- gemcitabine / Generic mfg.
The impact of anti-EGFR therapy when added to first-line standard platinum-gemcitabine chemotherapy in advanced biliary tract cancers: A meta-analysis of randomized studies. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5098;
Panitumumab was used in two studies while cetuximab and erlotinib were used in one study each... This is the first meta-analysis to show the addition of anti-EGFR agents to the standard first-line platinum-gemcitabine chemotherapy improves OS and PFS in advanced BTC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Frequency of KRAS, NRAS, and BRAF mutations in colorectal cancer in an Argentinian population. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4960;
Mutations in RAS genes arose in 38-47% of mCRC patients before 1L. BRAF mutations were found in 12.1-13.3% slightly higher than in other series.
- Long-term survivors (LTSs) population of metastatic colorectal cancer (mCRC): A Northern Italian comprehensive cancer center experience. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4950;
Further analysis including the role of liquid biopsy is under investigation to identify prognostic and predictive biomarkers in order to improve survival outcomes. >
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Circulating tumor DNA in decision-making of patients with metastatic colorectal cancer after failure of first-line treatment containing cetuximab: A single-center, phase II trial. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4945;
P2
The bevacizumab-based second line treatment increases DCR and PFS than continuously cetuximab-based treatment, and had a better tendency in OS. Clinical trial information: NCT04831528.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
A phase II clinical trial of prior regimen rechallenge in third- or later-line treatment for patients with metastatic colorectal cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4944;
P2
For the patients with heavily treated mCRC, the re-application of chemotherapy with front-line treatment regimen has shown a decent effectiveness with acceptable safety. Clinical trial information: NCT03485027.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
The multi-omics signature to predict sensitive to anti-epidermal growth factor receptor therapy in RAS wild-type colorectal cancer liver metastases. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4939;
P4
The multi-omics signature can serve as an intermediate surrogate marker of anti-EGFR treatment sensitivity and survival. The signature outperformed known biomarkers in providing an early prediction of treatment sensitivity and could be used to RAS wild type mCRC treatment decisions.
- 5-fluorouracil / Generic mfg.
Chemotherapy and radiofrequency hyperthermia (oncothermia) in the treatment of metastatic colorectal cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4932;
Despite the limitations of this observation, activity of this multi-modality treatment appears promising. Prospective randomized trials are needed to confirm these findings.
- Zelboraf (vemurafenib) / Roche
Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4929;
V+Co showed antitumor effects in CRC BRAF mutated patients who were heavily pre-treated. More randomized trials needed.